These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35944897)

  • 1. Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics.
    Chianese U; Papulino C; Passaro E; Evers TM; Babaei M; Toraldo A; De Marchi T; Niméus E; Carafa V; Nicoletti MM; Del Gaudio N; Iaccarino N; Randazzo A; Rotili D; Mai A; Cappabianca S; Mashaghi A; Ciardiello F; Altucci L; Benedetti R
    Mol Metab; 2022 Oct; 64():101561. PubMed ID: 35944897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
    Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN
    Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.
    Duan L; Chen YA; Liang Y; Chen Z; Lu J; Fang Y; Cao J; Lu J; Zhao H; Pong RC; Hernandez E; Kapur P; Tran TAT; Smith T; Martinez ED; Ahn JM; Hsieh JT; Luo JH; Liu ZP
    Biomed Pharmacother; 2023 Feb; 158():114077. PubMed ID: 36495660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer.
    Benedetti R; Dell'Aversana C; De Marchi T; Rotili D; Liu NQ; Novakovic B; Boccella S; Di Maro S; Cosconati S; Baldi A; Niméus E; Schultz J; Höglund U; Maione S; Papulino C; Chianese U; Iovino F; Federico A; Mai A; Stunnenberg HG; Nebbioso A; Altucci L
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31888209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.
    Li M; Liu M; Han W; Wang Z; Han D; Patalano S; Macoska JA; Balk SP; He HH; Corey E; Gao S; Cai C
    Cancer Res; 2023 May; 83(10):1684-1698. PubMed ID: 36877164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion.
    Wang J; Yu Q; Qiu Z; Dai T; Wang S; Yang X; Evers BM; Wu Y
    Aging (Albany NY); 2020 Jan; 12(1):397-415. PubMed ID: 31901895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
    Li X; Li T; Chen D; Zhang P; Song Y; Zhu H; Xiao Y; Xing Y
    Oncol Rep; 2016 Jan; 35(1):584-92. PubMed ID: 26534764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.
    Han W; Liu M; Han D; Li M; Toure AA; Wang Z; Besschetnova A; Patalano S; Macoska JA; Gao S; He HH; Cai C
    Oncogene; 2022 Feb; 41(6):852-864. PubMed ID: 34975152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
    Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
    Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of histone lysine demethylases in prostate cancer.
    Crea F; Sun L; Mai A; Chiang YT; Farrar WL; Danesi R; Helgason CD
    Mol Cancer; 2012 Aug; 11():52. PubMed ID: 22867098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.
    Liang Y; Ahmed M; Guo H; Soares F; Hua JT; Gao S; Lu C; Poon C; Han W; Langstein J; Ekram MB; Li B; Davicioni E; Takhar M; Erho N; Karnes RJ; Chadwick D; van der Kwast T; Boutros PC; Arrowsmith CH; Feng FY; Joshua AM; Zoubeidi A; Cai C; He HH
    Cancer Res; 2017 Oct; 77(20):5479-5490. PubMed ID: 28916652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
    Shen T; Dong B; Meng Y; Moore DD; Yang F
    Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2205350119. PubMed ID: 36251994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CACUL1 functions as a negative regulator of androgen receptor in prostate cancer cells.
    Choi H; Lee SH; Um SJ; Kim EJ
    Cancer Lett; 2016 Jul; 376(2):360-6. PubMed ID: 27085459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
    Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
    Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy.
    Wan X; Pu H; Huang W; Yang S; Zhang Y; Kong Z; Yang Z; Zhao P; Li A; Li T; Li Y
    Oncotarget; 2016 Aug; 7(32):51284-51300. PubMed ID: 27323416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.